Age-Related Macular Degeneration/Diabetic Macular Edema/Macular Edema secondary to Retinal Vein Occlusion
Conditions
Interventions
Case series:Ranibizumab
Sponsors
Zhongshan Ophthalmic Center, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Male or female patient = 18 years old; 2. Presence of visual impairment due to wAMD, DME and edema secondary to RVO; 3. Patients who are prescribed with ranibizumab, based on current approved indications; 4. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Simultaneous participation in a study that includes administration of any investigation drug or procedure; 2. Systemic treatment with any VEGF inhibitor in the 90 days prior to enrollment; 3. Ocular treatment with any VEGF inhibitor other than ranibizumab in the month prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of ranibizumab injections;Number of other intraocular injections;Number of visits;Time interval between injections;Number and reason of switching treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compare naiive patients and prior treated patients for the visual outcomes;Mean change of BCVA;Mean change of centraLretina thickness;Change of intraretinal fluid (IRF), subretinal fluid (SRF);Determine the relationship between injection number and VA improvement;Determine relationship between time period from the moment being diagnosed to first injection;Compare reimbursed/ non-reimbursed patients for the treatment pattern and visual;The safety objective of this study will be assessed based on the incidence rate, relationship and severity; | — |
Countries
China
Contacts
Public ContactLin Lv
Zhongshan Ophthalmic Center, Sun Yat-sen University
Outcome results
None listed